Results 1 to 10 of about 87,300 (320)

Comparison of GRACE and TIMI risk scores in the prediction of in-hospital and long-term outcomes among East Asian non-ST-elevation myocardial infarction patients

BMC Cardiovascular Disorders, 2022
Background Risk stratification in non-ST segment elevation myocardial infarction (NSTEMI) determines the intervention time. Limited study compared two risk scores, the Thrombolysis in Myocardial Infarction (TIMI) and Global Registry of Acute Coronary ...
Lu Yanqiao, Lan Shen, Miao Yutong, Shen Linghong, He Ben   +4 more
doaj   +2 more sources

Indirect comparison of TIMI, HEART and GRACE for predicting major cardiovascular events in patients admitted to the emergency department with acute chest pain: a systematic review and meta-analysis

BMJ Open, 2021
Background The study aimed to compare the predictive values of the thrombolysis in myocardial infarction (TIMI); History, Electrocardiography, Age, Risk factors and Troponin (HEART) and Global Registry in Acute Coronary Events (GRACE) scoring systems for
Yiwei Chen, Xiaoping Wang, Feng Chen, Zhiyong Wu, Jun Ke   +4 more
doaj   +2 more sources

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study

Diabetes, Obesity and Metabolism, 2019
To investigate cardiovascular (CV) safety and event rates for dapagliflozin versus other glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the main inclusion criteria and outcomes from the DECLARE‐TIMI 58 study.
Anna Norhammar, Johan Bodegard, Thomas Nyström   +2 more
exaly   +2 more sources

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54 [PDF]

European Heart Journal - Cardiovascular Pharmacotherapy, 2019
Aims In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15–16% in stable patients with a prior myocardial infarction (MI) 1–3 years earlier.
Mikael Dellborg, Marc P. Bonaca, Robert F. Storey, Philippe Gabríel Steg, Kyung Ah Im, Marc Cohen, Deepak L. Bhatt, Ton Oude Ophuis, Andrzej Budaj, Christian W. Hamm, Jindřich Špinar, Róbert Gábor Kiss, José López‐Sendón, Gabriel Kamenský, Frans Van de Werf, Diego Ardissino, Frederic Kontny, Gilles Montalescot, Per Johanson, Olof Bengtsson, Anders Himmelmänn, Eugene Braunwald, Marc S. Sabatine   +22 more
openalex   +2 more sources

Comparison of the GRACE, HEART and TIMI score to predict major adverse cardiac events in chest pain patients at the emergency department

International Journal of Cardiology, 2017
J. Poldervaart, M. Langedijk, B. Backus, Ineke M C Dekker, A. J. Six, P. Doevendans, A. Hoes, J. Reitsma   +7 more
exaly   +2 more sources

Assessing the Real Impact of Open-Source Components in Software Systems

IEEE Access, 2023
Open-source libraries form the backbone of modern software systems, making software composition analysis (SCA) a vital part of the software development cycle. Despite its importance, current SCA methods, primarily focusing on open-source component issues,
Andy Molin, Andrei Mario Rivis, Radu Marinescu   +2 more
doaj   +1 more source

An Analysis of Extended and Dilated Filters in Sharpening Algorithms

IEEE Access, 2023
Digital imaging is omnipresent nowadays due to the expansion of the mobile device industry and its use cases. However, the diversity of sensors and hardware limitations often lead to images not meeting desired quality standards.
Ciprian Orhei, Radu Vasiu
doaj   +1 more source

Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

Circulation, 2022
Background: Genetic loss-of-function variants in ANGPTL3 are associated with lower levels of plasma lipids. Vupanorsen is a hepatically targeted antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Methods: Adults with
Brian A. Bergmark, N. Marston, C. Bramson, M. Curto, V. Ramos, Alexandra Jevne, J. Kuder, Jeong-Gun Park, S. Murphy, S. Verma, W. Wojakowski, S. Terra, M. Sabatine, S. Wiviott   +13 more
semanticscholar   +1 more source

Role of ST‐Segment Resolution Alone and in Combination With TIMI Flow After Primary Percutaneous Coronary Intervention for ST‐Segment–Elevation Myocardial Infarction

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2023
Background To evaluate the role of ST‐segment resolution (STR) alone and in combination with Thrombolysis in Myocardial Infarction (TIMI) flow in reperfusion evaluation after primary percutaneous coronary intervention (PPCI) for ST‐segment–elevation ...
Chao Wu, Xiaojin Gao, Ling Li, Quanmin Jing, Weimin Li, Haiyan Xu, Wenbo Zhang, Sidong Li, Yanyan Zhao, Yang Wang, Wei Li, Yongjian Wu, F. Hu, Chen Jin, Shubin Qiao, Jingang Yang, Yue-jing Yang   +16 more
semanticscholar   +1 more source

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Diabetes Care, 2021
OBJECTIVE Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve albuminuria in patients with high cardiorenal risk. We report albuminuria change in the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) cardiovascular outcome trial ...
Ofri Mosenzon, S. Wiviott, Hiddo J. L. Heerspink, J. Dwyer, A. Cahn, Erica L. Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, S. Murphy, Thomas A. Zelniker, I. Gause-Nilsson, A. Langkilde, M. Fredriksson, P. Johansson, Deepak L. Bhatt, Lawrence A Leiter, D. McGuire, John P H Wilding, M. Sabatine, I. Raz   +20 more
semanticscholar   +1 more source